On May 4th and 5th, 2022 the elephants team participated in the Kick-off Meeting of the TAONas-LUAD EIC Transition Grant at Centre for Genomic Regulation (CRG). Elena Canetti, Jesús Purroy, Cristina Vilarmau Marsinyach, and Isabel Espejo Díaz from Inveniam Group attended the event. We are honored to be an official member of this EIC consortium with CRG, SINTEF, and INSERM. The TAONas-LUAD project aims to develop an innovative therapy based on the use of Antisense Oligonucleotides (AONs) that regulate alternative splicing (AS) to target a pro-proliferative protein isoform observed in the vast majority of Lung adenocarcinomas (LUAD) tumors. The technology developed by Juan Valcarcel and Jordi Hernández PhD MBA at CRG will be adapted for non-viral lipid nanoparticles delivery by Dr. Sven Even Borgo’s group from SINTEF and validated in vivo using lung cancer xenographs models at Dr. Antonio Maraver’s lab from INSERM.
Inveniam Group will support the implementation of the market and business strategy of the project. We will also collaborate on defining the project’s regulatory roadmap and communication strategy.
We want to thank the TAONas-LUAD consortium members for inviting Inveniam Group into the team. It was two amazing days surrounded by this outstanding team of scientists, which left everyone feeling inspired by the rewarding scientific discussions. Inveniam Group could not be more proud to say that we will contribute to making this project a reality, bringing TAONas-LUAD technology closer to the market and closer to being a future therapy for lung cancer patients!
We look forward to keeping learning and working with this team during the next four years.